|
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck |
Greenhalgh J, Bagust A, Boland A, Fleeman N, McLeod C, Dundar Y, Proudlove C, Shaw R |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Greenhalgh J, Bagust A, Boland A, Fleeman N, McLeod C, Dundar Y, Proudlove C, Shaw R. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technology Assessment 2009; 13(Suppl 3 Article 8): 49-54 Indexing Status Subject indexing assigned by NLM MeSH Antibodies, Monoclonal /administration & Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Carcinoma, Squamous Cell /drug therapy /pathology; Cetuximab; Cost-Benefit Analysis; Cyclophosphamide /administration & Head and Neck Neoplasms /drug therapy /pathologys; Neoplasm Metastasis; Neoplasm Recurrence, Local /drug therapy /pathology; Randomized Controlled Trials as Topic; dosage /economics /therapeutic use; dosage /therapeutic use Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32013000637 Date abstract record published 19/08/2013 |
|
|
|